1.Sun LY, Wijeysundera DN, Tait GA, Beattie WSJATJotASoA. Association of intraoperative hypotension with acute kidney injury after elective noncardiac surgery. 2015;123:515–23.
2.Ng RRG, Chew STH, Liu W, Shen L, Ti LKJTJot, surgery c. Identification of modifiable risk factors for acute kidney injury after coronary artery bypass graft surgery in an Asian population. 2014;147:1356–61.
3.Lee E-H, Kim, Wook-Jong,Kim, Ji-Yeon,Chin, Ji-Hyun,Choi, Dae-Kee,Sim, Ji-Yeon,Choo, Suk-Jung,Chung, Cheol-Hyun,Lee, Jae-Won,Choi, In-Cheol. Effect of exogenous albumin on the incidence of postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass surgery with a preoperative albumin level of less than 4.0 g/dl. J Anesthesiology 2016;124:1001–11.
4.Lee E-H, Baek, Seung-Hee,Chin, Ji-Hyun,Choi, Dae-Kee,Son, Hyo-Jung,Kim, Wook-Jong,Hahm, Kyung-Don,Sim, Ji-Yeon,Choi, In-Cheol. Preoperative hypoalbuminemia is a major risk factor for acute kidney injury following off-pump coronary artery bypass surgery. J Intensive care medicine 2012;38:1478–86.
5.Kim M, Brady, Joanne E,Li, Guohua. Variations in the risk of acute kidney injury across intraabdominal surgery procedures. J Anesthesia Analgesia 2014;119:1121–32.
6.Goren O, Levy A, Cattan A, Lahat G, Matot IJTAJoS. Acute kidney injury in pancreatic surgery; association with urine output and intraoperative fluid administration. 2017;214:246–50.
7.Garg AX, Kurz, Andrea,Sessler, Daniel I,Cuerden, Meaghan,Robinson, Andrea,Mrkobrada, Marko,Parikh, Chirag R,Mizera, Richard,Jones, Philip M,Tiboni, Maria. Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. J Jama 2014;312:2254–64.
8.Futier E, Lefrant, Jean-Yves,Guinot, Pierre-Gregoire,Godet, Thomas,Lorne, Emmanuel,Cuvillon, Philippe,Bertran, Sebastien,Leone, Marc,Pastene, Bruno,Piriou, Vincent. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. J Jama 2017;318:1346–57.
9.Bress AP, Kramer, Holly,Khatib, Rasha,Beddhu, Srinivasan,Cheung, Alfred K,Hess, Rachel,Bansal, Vinod K,Cao, Guichan,Yee, Jerry,Moran, Andrew E. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey). J Circulation 2017;135:1617–28.
10.Wilson T, Quan, Samuel,Cheema, Kim,Zarnke, Kelly,Quinn, Rob,de Koning, Lawrence,Dixon, Elijah,Pannu, Neesh,James, Matthew T. Risk prediction models for acute kidney injury following major noncardiac surgery: systematic review. J Nephrology Dialysis Transplantation 2015;31:231–40.
11.Donati A, Ruzzi, M,Adrario, E,Pelaia, P,Coluzzi, F,Gabbanelli, V,Pietropaoli, P. A new and feasible model for predicting operative risk. Br J Anaesth 2004;93:393–9.
12.Sacks FM, Tonkin, Andrew M,Craven, Timothy,Pfeffer, Marc A,Shepherd, James,Keech, Anthony,Furberg, Curt D,Braunwald, Eugene. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. J Circulation 2002;105:1424–8.
13.Barter P, Gotto, Antonio M,LaRosa, John C,Maroni, Jaman,Szarek, Michael,Grundy, Scott M,Kastelein, John JP,Bittner, Vera,Fruchart, Jean-Charles. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. J New England Journal of Medicine 2007;357:1301–10.
14.Acharjee S, Boden, William E,Hartigan, Pamela M,Teo, Koon K,Maron, David J,Sedlis, Steven P,Kostuk, William,Spertus, John A,Dada, Marcin,Chaitman, Bernard R. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Journal of the American College of Cardiology 2013;62:1826–33.
15.Mora S, Glynn RJ, Ridker PMJC. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. 2013;128:1189–97.
16.Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora SJJotACoC. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). 2012;60:508–16.
17.Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJJM. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. 2008;57:77–83.
18.Briel M, Ferreira-Gonzalez, I., You, J. J., Karanicolas, P. J., Akl, E. A., Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A. and Whitt, I. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ;338 (2009):b92.
19.Rosenson RS, Brewer Jr, H Bryan,Davidson, W Sean,Fayad, Zahi A,Fuster, Valentin,Goldstein, James,Hellerstein, Marc,Jiang, Xian-Cheng,Phillips, Michael C,Rader, Daniel J. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012;125:1905–19.
20.Haase CL, Tybjærg-Hansen A, Grande P, Frikke-Schmidt RJTJoCE, Metabolism. Genetically elevated apolipoprotein AI, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. 2010;95:E500-E10.
21.Haase CL T-HA, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. The Journal of Clinical Endocrinology & Metabolism 2012;97:E248-E56.
22.Rosenson RS BJH, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.. Circulation 2013;128(11):1256–67.
23.Kuhn FE ME, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. The American journal of cardiology 1991;68.15:1425–30.
24.Oram JF, Carolyn J. Johnson, and T. Aulinskas Brow. Interaction of high density lipoprotein with its receptor on cultured fibroblasts and macrophages. Evidence for reversible binding at the cell surface without internalization. J Biol Chem 1987;262.5:2405–10.
25.Kontush A, Sandrine Chantepie, and M. John Chapman. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol;23.10 (2003):1881–8.
26.Soran H SJ, Liu Y, Durrington PN. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae. Current opinion in lipidology 26.4 (2015):247–56.
27.Barter PJ NS, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL.. Circ Res (2004);95(8):764–72.
28.Murphy AJ, Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C. L., Wang, M., Sanson, M., Abramowicz, S., Welch, C. and Bochem, A. E. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. The Journal of clinical investigation;121.10 (2011):4138–49.
29.Saku K, Masood Ahmad, Pia Glas-Greenwalt, and Moti L. Kashyap. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res;39.1 (1985):1–8.
30.Griffin JH, Kazuhisa Kojima, Carole L. Banka, Linda K. Curtiss, and José A. Fernández. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. The Journal of clinical investigation;103.2 (1999): 219–27.
31.Epand RM, Alan Stafford, Bryan Leon, Philippa E. Lock, Ewan M. Tytler, Jere P. Segrest, and G. M. Anantharamaiah. HDL and apolipoprotein AI protect erythrocytes against the generation of procoagulant activity. Arteriosclerosis and thrombosis: a journal of vascular biology 14.11 (1994):1775–83.
32.Aoyama T, Yoshiki Yui, Hiroshi Morishita, and Chuichi Kawai. Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation;81.6 (1990):1784–91.
33.Yamamoto S, Yancey, Patricia G,Ikizler, T Alp,Jerome, W Gray,Kaseda, Ryohei,Cox, Brian,Bian, Aihua,Shintani, Ayumi,Fogo, Agnes B,Linton, MacRae F. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012;60:2372–9.
34.Shroff R, Speer, Thimoteus,Colin, Sophie,Charakida, Marietta,Zewinger, Stephen,Staels, Bart,Chinetti-Gbaguidi, Giulia,Hettrich, Inga,Rohrer, Lucia,O’Neill, Francis. HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol 2014;25:2658–68.
35.Kalantar-Zadeh K, Kopple J, Kamranpour N, Fogelman A, Navab MJKi. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. 2007;72:1149–56.
36.Zheng Z, Jayaram, Raja,Jiang, Lixin,Emberson, Jonathan,Zhao, Yan,Li, Qi,Du, Juan,Guarguagli, Silvia,Hill, Michael,Chen, Zhengming. Perioperative rosuvastatin in cardiac surgery. N Engl J Med 2016;374:1744–53.
37.Park JH, Shim J-K, Song J-W, Soh S, Kwak Y-LJIcm. Effect of atorvastatin on the incidence of acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. 2016;42:1398–407.
38.Billings FT, Hendricks, Patricia A,Schildcrout, Jonathan S,Shi, Yaping,Petracek, Michael R,Byrne, John G,Brown, Nancy J. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA 2016;315:877–88.
39.Smith LE, Smith, Derek K,Blume, Jeffrey D,Linton, MacRae F,Billings IV, Frederic T. High‐Density Lipoprotein Cholesterol Concentration and Acute Kidney Injury After Cardiac Surgery. Journal of the American Heart Association 2017;6:e006975.